Capecitabine

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Colorectal Cancer

Conditions

Colorectal Cancer

Trial Timeline

Aug 1, 2005 → Mar 1, 2007

NCT ID

NCT02581423

About Capecitabine

Capecitabine is a approved stage product being developed by Roche for Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02581423. Target conditions include Colorectal Cancer.

What happened to similar drugs?

14 of 20 similar drugs in Colorectal Cancer were approved

Approved (14) Terminated (3) Active (5)

✅Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2MerckApproved

✅Cetuximab (EGFR inhibitor) + Bevacizumab + Irinotecan (CPT-11) + Oxaliplatin + Leucovorin and 5-FU + CapecitabineMerckApproved

✅5-FU based doublet chemotherapy + bevacizumabRocheApproved

✅capecitabine [Xeloda]RocheApproved

✅5-Fluorouracil + Bevacizumab + Irinotecan + OxaliplatinRocheApproved

✅Oxaliplatin + Capecitabine + Bevacizumab + Leucovorin + 5-Fluouracil + IrinotecanRocheApproved

✅CapecitabineRocheApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01725386	Pre-clinical	Completed	Mar 1, 2011	Feb 1, 2015	Breast Cancer
NCT01664494	Pre-clinical	Completed	Apr 1, 2010	Jul 1, 2012	Breast Cancer, Colorectal Cancer, Gastric Cancer
NCT01167049	Phase 2	UNKNOWN	Aug 1, 2009	Dec 1, 2013	Gastric Cancer
NCT00434941	Phase 2	Terminated	Sep 1, 2007	Jan 1, 2009	Breast Cancer
NCT01118377	Phase 2	Completed	May 1, 2007	Apr 1, 2013	Brainstem Glioma
NCT00347438	Phase 2	Terminated	Sep 1, 2006	Mar 1, 2013	Breast Cancer
NCT00130533	Phase 3	Completed	Jan 1, 2006	Feb 17, 2017	Breast Cancer
NCT02581423	Approved	Completed	Aug 1, 2005	Mar 1, 2007	Colorectal Cancer
NCT00196820	Phase 2	Completed	Jul 1, 2005	Dec 1, 2008	Breast Cancer
NCT02567331	Approved	Completed	Oct 1, 2004	Apr 1, 2006	Colorectal Cancer
NCT00148720	Phase 2	Terminated	Sep 1, 2004	—	Invasive Breast Carcinoma
NCT00095901	Phase 2	Completed	Jun 1, 2004	May 1, 2007	Head and Neck Cancer
NCT00176787	Phase 2	Terminated	Oct 1, 2000	Jun 1, 2007	Rectal Cancer

Competing Products

20 competing products in Colorectal Cancer

See all competitors

Product	Company	Stage	Hype Score
Cetuximab + Oxaliplatin + Capecitabine	Eli Lilly	Phase 2	35
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FU	Eli Lilly	Phase 2	35
ZN-c3 + Encorafenib + Cetuximab	Zentalis Pharmaceuticals	Phase 1	11
ALIMTA + Oxaliplatin	Eli Lilly	Phase 2	35
eFT508 + Avelumab	eFFECTOR Therapeutics	Phase 2	25
Bevacizumab + Oxaliplatin + Capecitabine	Chugai Pharmaceutical	Phase 1/2	32
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + Capecitabine	Chugai Pharmaceutical	Phase 2	31
FOLFIRI + FOLFOX-4 + FOLFIRI-HD + FOLFOX-7 + FOLFIRINOX	Chugai Pharmaceutical	Phase 2/3	38
Gemcitabine and UFTE chemotherapy	Yuhan	Phase 2	35
CPT-11 and TS-1 + CPT-11, 5-FU and l-LV	Daiichi Sankyo	Phase 2/3	38
CPT-11 based regimens	Daiichi Sankyo	Pre-clinical	26
CS7017 + irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)	Daiichi Sankyo	Phase 2	35
Tivantinib + Placebo + Cetuximab + Irinotecan	Daiichi Sankyo	Phase 1/2	32
DS-8201a 5.4 mg/kg Q3W + DS-8201a 6.4 mg/kg Q3W	Daiichi Sankyo	Phase 2	35
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	39
CS-1008 + irinotecan	Daiichi Sankyo	Phase 2	27
CS-7017 + Placebo	Daiichi Sankyo	Phase 2	27
Patritumab Deruxtecan	Daiichi Sankyo	Phase 2	27
CS-1008 + FOLFIRI	Daiichi Sankyo	Phase 1	29
DS-8273a + nivolumab	Daiichi Sankyo	Phase 1	21